A Phase 3 Randomized Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma (CA209-76K)
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
